

# UC Irvine

## UC Irvine Previously Published Works

### Title

IRAK-M Expression Limits Dendritic Cell Activation and Proinflammatory Cytokine Production in Response to Helicobacter pylori

### Permalink

<https://escholarship.org/uc/item/7dt1d9zn>

### Journal

PLOS ONE, 8(6)

### ISSN

1932-6203

### Authors

Shiu, Jessica  
Czinn, Steven J  
Kobayashi, Koichi S  
[et al.](#)

### Publication Date

2013

### DOI

10.1371/journal.pone.0066914

Peer reviewed

# IRAK-M Expression Limits Dendritic Cell Activation and Proinflammatory Cytokine Production in Response to *Helicobacter pylori*

Jessica Shiu<sup>1</sup>, Steven J. Czinn<sup>1</sup>, Koichi S. Kobayashi<sup>2</sup>, Yezhou Sun<sup>3</sup>, Thomas G. Blanchard<sup>1\*</sup>

**1** University of Maryland School of Medicine, Baltimore, Maryland, United States of America, **2** Texas A&M College of Medicine, College Station, Texas, United States of America, **3** Institute for Genomic Sciences, University of Maryland School of Medicine, Baltimore, Maryland, United States of America

## Abstract

*Helicobacter pylori* (*H. pylori*) infects the gastric mucosa and persists for the life of the host. Bacterial persistence may be due to the induction of regulatory T cells ( $T_{reg}$ s) which may have protective effects against other diseases such as asthma. It has been shown that *H. pylori* modulates the T cell response through dendritic cell reprogramming but the molecular pathways involved are relatively unknown. The goal of this study was to identify critical elements of dendritic cell (DC) activation and evaluate potential influence on immune activation. Microarray analysis was used to demonstrate limited gene expression changes in *H. pylori* stimulated bone marrow derived DCs (BMDCs) compared to the BMDCs stimulated with *E. coli*. IRAK-M, a negative regulator of TLR signaling, was upregulated and we selected it for investigation of its role in modulating the DC and T cell responses. IRAK-M<sup>-/-</sup> and wild type BMDC were compared for their response to *H. pylori*. Cells lacking IRAK-M produced significantly greater amounts of proinflammatory MIP-2 and reduced amounts of immunomodulatory IL-10 than wild type BMDC. IRAK-M<sup>-/-</sup> cells also demonstrated increased MHC II expression upon activation. However, IRAK-M<sup>-/-</sup> BMDCs were comparable to wild type BMDCs in inducing T-helper 17 ( $T_H17$ ) and  $T_{reg}$  responses as demonstrated in vitro using BMDC CD4<sup>+</sup> T cells co-culture assays, and in vivo through the adoptive transfer of CD4<sup>+</sup> FoxP3-GFP T cells into *H. pylori* infected IRAK-M<sup>-/-</sup> mice. These results suggest that *H. pylori* infection leads to the upregulation of anti-inflammatory molecules like IRAK-M and that IRAK-M has a direct impact on innate functions in DCs such as cytokine and costimulation molecule upregulation but may not affect T cell skewing.

**Citation:** Shiu J, Czinn SJ, Kobayashi KS, Sun Y, Blanchard TG (2013) IRAK-M Expression Limits Dendritic Cell Activation and Proinflammatory Cytokine Production in Response to *Helicobacter pylori*. PLoS ONE 8(6): e66914. doi:10.1371/journal.pone.0066914

**Editor:** Susan Kovats, Oklahoma Medical Research Foundation, United States of America

**Received:** February 28, 2013; **Accepted:** May 10, 2013; **Published:** June 11, 2013

**Copyright:** © 2013 Shiu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by National Institutes of Health grants AI-055710, and DK-46461, and Canadian Institutes of Health Research grant DFSA-236840. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

\* E-mail: tblanchard@ped.s.umaryland.edu

## Introduction

*Helicobacter pylori* (*H. pylori*) colonizes the gastric mucosa of over half of the world's population [1]. Infection lasts for life and is associated with a variety of gastric diseases including peptic ulcer disease, gastric adenocarcinoma, and MALT lymphoma [1–7]. Greater than 80% of infected people do not develop disease but even asymptomatic individuals develop histologic gastritis [8,9]. The lack of disease in most individuals was originally believed to be due in part to variations in bacterial virulence mechanisms between *H. pylori* strains. It is becoming increasingly evident however that limited disease is due in large part to host immunoregulatory mechanisms, a response that also favors bacterial persistence [10–17].

The development of histologic gastritis is T cell-dependent and is predominantly driven by a mix of  $T_H1$  and  $T_H17$  responses [18–23]. Despite the role of these T helper subsets in promoting inflammation, it has been shown that regulatory T cells ( $T_{reg}$ s) accumulate in the gastric mucosa during chronic *H. pylori* infection and contribute to persistent *H. pylori* colonization [10,13–15,17]. The loss of regulatory T cell function in murine models of *Helicobacter* infection results in significantly increased inflammation and reduced bacterial loads, demonstrating that these *H. pylori*-


mediated immunomodulatory effects may be beneficial to the host and the bacteria [10,15,16]. The benefits to the host extend beyond the stomach as *H. pylori* infection has been inversely correlated with esophageal cancer in adults and wheezing in children. The protective effects of *H. pylori* infection may be dependent on  $T_{reg}$ s [24–27].

Down regulation of the host immune response is mediated by regulatory T cells but the bacterial, environmental, and cellular factors that promote the activation of regulatory T cells remain ill-defined for *H. pylori* infection. Dendritic cells (DCs) are potent antigen-presenting cells that are critical for the induction of downstream adaptive immune responses [28,29] and they have been demonstrated to play an important role in *H. pylori* infection. DCs sense *H. pylori* primarily through Toll-like receptors (TLR) 2 and 4 in a MyD88 dependent manner [30,31]. *H. pylori* infection however may skew the DC response to favor the generation of  $T_{reg}$  cells via IL-18 dependent mechanisms [12,27]. This Treg response, influenced by DCs, also protects against asthma in mice [32].

A better understanding of how *H. pylori* affects DC function and how DCs regulate downstream immune events may provide additional insight into *H. pylori* pathogenesis and persistence but

may also enhance our understanding of the host response to mucosal bacteria in general. One of the mechanisms employed by the host to limit microbial induced activation of APCs is the expression of interleukin-1 receptor-associated kinase M (IRAK-M), a negative regulator of TLR [33]. IRAK-M expression has been demonstrated to limit immune activation to specific pathogens, and to play a role in maintaining immune homeostasis in the gut through its induction by commensal bacteria [33–36].

We observed upregulation of IRAK-M in a transcriptome analysis of *H. pylori* stimulated DCs, one of only ten genes to be induced. The purpose of the present study therefore was to characterize the role of IRAK-M in *H. pylori*-activated DCs and to determine whether IRAK-M influences activation of the T cell response. We now report that IRAK-M expression in DCs is dependent upon TLR activation, and its expression is associated with limiting the



**Figure 1. Global gene expression level changes in BMDCs stimulated with media alone, *H. pylori* or *E. coli* after 24 h.** cRNA was hybridized onto Illumina Mouse Ref8\_v2.0 chips with probes for >24,000 genes (n=3 for antigen lysate treated BMDCs, n=2 for media treated BMDCs). (A) The number of genes that were upregulated or downregulated in both treated groups compared to media alone. Data reflects probes with an FDR <0.1. (B) RT-PCR analysis confirmed that IRAK-M was significantly upregulated in BMDCs stimulated with either *H. pylori* or *E. coli* compared to media alone at 4 h, 8 h and 24 h. (C) At 24 h, both Flt3L and GM-CSF derived BMDCs upregulated IRAK-M expression after stimulation with either live SS1 bacteria (MOI 10), or SS1 and 26695 antigen lysate. \*\*,  $P < 0.01$ . doi:10.1371/journal.pone.0066914.g001

innate proinflammatory activity of the DC, as well as maturation as measured by MHC II expression.

## Methods

### Ethics Statement

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocols were approved by the Institutional Animal Care and Use Committee of the University of Maryland in Baltimore (#0809004). All efforts were made to minimize pain and suffering.

### Mice

Six- to thirteen-week-old C57BL/6, TLR2<sup>-/-</sup>, and TLR4<sup>-/-</sup> mice were obtained from Jackson Laboratory (Bar Harbor, ME). IRAK-M deficient mice were derived on a C57BL/6 background as described previously [33] and were bred homozygously at the University of Maryland School of Medicine (Baltimore, MD, USA). C57BL/6 FoxP3-GFP mice and C57BL/6 OT-II Foxp3-GFP mice were a generous gift from David Scott (Bethesda, MD, USA) [37]. All animals were housed under pathogen-free conditions in microisolator cages at the University of Maryland Baltimore animal facilities. Mice were euthanized for tissue collection by CO<sub>2</sub> asphyxiation followed by thoracotomy.

### Bacterial Strains and Infection

*E. coli* K12 was purchased from ATCC (#29425) (Manassas, VA) and grown on LB plates supplemented with amphotericin B (2.5 µg/ml). The mouse-adapted *H. pylori* Sydney Strain 1 (SS1) [38] and strain 26695 (ATCC #700392) were grown on Columbia agar (Difco, Detroit, MI) supplemented with 7% horse blood and antibiotics at 37°C. For inoculation of mice, bacteria were transferred to 10 ml Brucella broth (Difco) supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA) and amphotericin B (2.5 µg/ml). Liquid cultures were established in T25 flasks and maintained at 37°C with 10% CO<sub>2</sub>. Infections with *H. pylori* SS1 were performed by delivering 1 × 10<sup>7</sup> CFU in 0.5 ml Brucella broth by oral gavage using a 20 G feeding needle

attached to a 1cc syringe. Antigen lysates were prepared as previously described [39].

### Generation of BMDCs and in Vitro Stimulation Assays

Femurs and tibias were removed from 6–14 week old C57BL/6 WT, TLR2<sup>-/-</sup>, TLR4<sup>-/-</sup>, and IRAK-M<sup>-/-</sup> mice at necropsy. Bone marrow was flushed out with a syringe filled with RPMI 1640 and cells were cultured in RPMI medium supplemented with either 100 ng/mL Flt3L (R&D Systems, Minneapolis, MN) or 7 ng/ml GM-CSF, and 10% heat inactivated FBS. Bone marrow derived DC (BMDC) were recovered after 8–9 days and plated in 48 well plates at 1 × 10<sup>6</sup> cells/well. Stimulation of BMDCs was performed with 10 µg/mL of either *H. pylori* SS1 lysate, *H. pylori* 26695 lysate or *E. coli* K12 lysate. For stimulation with live bacteria, bacterial density was determined by optical density at 450 nm and used at a multiplicity of infection (MOI) of 10. Supernatants were collected at 4, 8, and 24 hours after addition of lysate for determination of TNFα, IL-10 and MIP-2 levels by quantitative enzyme linked immunosorbent assay (ELISA) using the relevant Duoset kits according to the manufacturer's instructions (R&D Systems).

### T Cell Co-culture Experiments

Coculture experiments were performed by plating 1 × 10<sup>5</sup> BMDCs per well in 96 well U-bottom plates and stimulating with 10 µg/mL OVA peptide. CD4<sup>+</sup> T cells were isolated from spleens from 6–14 week old C57BL/6 OT-II Foxp3-GFP mice using the CD4<sup>+</sup> MagCelect Isolation Kit (R&D Systems) according to the manufacturer's instructions. T cells were added 5 × 10<sup>5</sup> cells per well to the BMDC in 96 well plates in the presence of either T<sub>reg</sub> promoting conditions (20 ng/mL TGF-β (R&D Systems) & 25 U of mIL-2 (E-bioscience, San Diego, CA), or T<sub>H</sub>17 promoting conditions (2 ng/mL TGF-β (R&D Systems) & 20 ng/mL mIL-6 (Gemini Bio-products, Sacramento, CA). Alternatively, 1 × 10<sup>5</sup> BMDCs were plated in 96 well U-bottom plates and stimulated with media alone or 10 µg/mL *H. pylori* SS1 antigen lysate. CD4<sup>+</sup> T cells were isolated from spleens from 6–14 week old C57BL/6 mice infected with *H. pylori* SS1 and 5 × 10<sup>5</sup> T cells were added to the wells in the absence of any additional stimulation.

**Table 1.** *H. pylori* associated gene expression changes.

Gene Name	Fold Change ( <i>H. pylori</i> vs. Media alone)
<b>Antimicrobial peptides</b>	
Elastase 2, neutrophil (Ela2)	-4.76
Cathelicidin antimicrobial peptide (CAMP)	-3.27
Lipocalin 2 (Lcn2)	2.09
<b>Anti-inflammatory molecules</b>	
Zinc finger CCCH type containing 12A (Zc3h12a)	1.46
Acyloxyacyl hydrolase (Aoah)	1.53
Interleukin-1 receptor-associated kinase 3 (Irak3/IRAK-M)	2.21
Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta (Nfkbiz/κB-ζ)	2.71
Tribbles homolog 3 (Drosophila) (Trib3)	3.98
Vanin 3 (Vnn3)	4.06
<b>Trafficking Molecules</b>	
Vesicle transport through interaction with t-SNAREs homolog 1A (yeast) (Vti1a)	1.70

doi:10.1371/journal.pone.0066914.t001

## Flow Cytometry Analysis

T-cells were stained with anti-CD4-APC and anti-IL17A-PE (eBioscience). BMDCs were stained with anti-MHCII-Pacific Blue, anti-PD-L1 PE, anti-CD40 PE-Cy5, anti-CD86 PE-Cy5 (eBioscience). All cells were analysed using a LSRII flow cytometer (BD Biosciences, San Jose, CA). Data were analyzed by FlowJo7 software (Tree Star, Ashland, OR).

## Adoptive Transfer Experiments

CD4<sup>+</sup> T cells were isolated from the spleens of FoxP3-GFP mice using the MagCelect Mouse CD4<sup>+</sup> T cell isolation kit (R&D Systems) and sorted for GFP negative cells using a BD FACSAria flow cytometer. A total of  $2 \times 10^6$  CD4<sup>+</sup>, GFP<sup>-</sup> cells were transferred into WT and IRAK-M<sup>-/-</sup> recipients by tail vein injection. Animals were infected with SS1 on day 3 and animals were harvested at 8 weeks for analysis. RNA was isolated from gastric tissue using the RNeasy kit (Qiagen, Germantown, MD) and converted to cDNA for qPCR analysis of GFP expression.

## RNA Isolation, Microarray Processing and Microarray Statistical Analysis


BMDCs were recovered following stimulation at the indicated timepoints and RNA was isolated using the RNeasy kit (Qiagen). cRNA was prepared from RNA using the Illumina TotalPrep RNA amplification kit. cRNA samples were hybridized onto Illumina MouseRef8\_v2.0 bead array chips (San Diego, CA) containing 25,967 probes ( $n = 3$  for antigen lysate treated BMDCs,  $n = 2$  for media treated BMDCs). Analysis was performed using the limma R package to compare gene expression profiles among different stimulated groups compared to media-treated BMDCs. Only probes with a false discovery rate (FDR) of  $< 0.1$  were included. Raw and normalized data sets were deposited into the NCBI Gene Expression Omnibus database under accession number GSE 44954.

## Quantitative real-time PCR


Quantitative PCR analysis was performed by first converting 1  $\mu$ g RNA to cDNA using the Quantitect reverse transcription kit (Qiagen). cDNA was diluted 10-fold and PCR amplification was performed with an Eppendorf Realplex Instrument (Eppendorf AG, Hamburg, Germany) on 96 well plates with SYBR Green supermix (Fermentas, Glen Burnie, MD) in either duplicate or triplicate. Each reaction mixture contained: 12.5  $\mu$ L SYBR green mix, 11.1  $\mu$ L dH<sub>2</sub>O, 0.2  $\mu$ L each forward and reverse primers at 0.8  $\mu$ M, and 1  $\mu$ L cDNA. Primer sequences were as follows: IRAKM: TGAGCAACGGGACGCTTT (forward), GATTC-GAACGTGCCAGGAA (reverse) [40]; GAPDH: CCAGG-TTGTCTCCTGCGACTT (forward), CCTGTTGCTGTAG-CCGTATTCA (reverse); GFP: CCTGAAGTTCATCTGCAC-CACC (forward), CTGCTGGTAGTGGT- CGGCGAGC (reverse). Relative gene expression changes were calculated using the  $\Delta\Delta C_T$  method, and expression normalization was done using the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

## Statistical Analysis

Statistical analysis was performed using GraphPad Prism for Macintosh 5.0 c (GraphPad Software, San Diego, CA). The Mann-Whitney test was used for analysis of statistical significance and a  $P$  value  $< 0.05$  was considered significant.



**Figure 2. IRAK-M<sup>-/-</sup> BMDCs exhibited a more proinflammatory phenotype after *H. pylori* stimulation compared to WT BMDCs.** Supernatant from *H. pylori* antigen-stimulated WT and IRAK-M<sup>-/-</sup> BMDCs were collected at 4 h, 8 h and 24 h and used to determine (A) TNF $\alpha$ , (B) MIP-2, and (C) IL-10 levels by ELISA. Data reflects three independent experiments. Error bars indicate standard deviations. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ .  
doi:10.1371/journal.pone.0066914.g002




**Figure 3. BMDCs stimulated for 24 h with *H. pylori* antigen were collected for flow cytometry analysis to determine (A) MHC-II expression and (B) PD-L1 expression compared to cells in media alone and isotype controls.** Graphical representation of mean  $\pm$  SD from data collected from three individual experiments performed in duplicate is shown on the right. Graphical representation of surface expression (C) CD86 and (D) CD40 determined by flow cytometry analysis \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ . doi:10.1371/journal.pone.0066914.g003

## Results

### *H. pylori* Stimulation of BMDCs Results in Gene Expression Changes in a Limited Set of Genes after 24 hours


To identify the molecular pathways activated by *H. pylori* stimulation in DCs, we performed microarray analysis on BMDCs stimulated for 24 hours with either *E. coli* or *H. pylori* bacterial lysate. As expected, *E. coli*-stimulated BMDCs (EC-BMDCs) exhibited gene expression changes in many genes (Figure 1A). More than half of 2162 impacted genes were downregulated. Surprisingly, *H. pylori*-stimulated BMDCs (HP-BMDCs) showed

limited gene expression changes with only 10 genes significantly affected in their expression (Table 1). Six of the 10 genes are implicated in anti-inflammatory pathways. Since *H. pylori* has been demonstrated to activate DCs primarily through TLR2 and TLR4 [30,31], we were particularly interested in the increased expression of IRAK-M, a negative regulator of TLR signaling [33]. Using a qPCR approach, we confirmed that IRAK-M was indeed upregulated in BMDCs following activation with *H. pylori* lysate, and that in contrast to EC-BMDCs, IRAK-M expression in HP-BMDCs remained significantly high at 24 hour ( $P < 0.01$ ; Figure 1B). IRAK-M was demonstrated to be significantly upregulated in *H. pylori*-stimulated BMDC generated with either




**Figure 4.** (A) IRAK-M induction in BMDCs after *H. pylori* stimulation is dependent on TLR expression. RNA from WT, TLR2<sup>-/-</sup>, TLR4<sup>-/-</sup> BMDCs was collected at 4 h, 8 h and 24 h and converted to cDNA. qPCR was used to determine relative IRAK-M expression levels. The diagram represents mean  $\pm$  SD from data collected from two individual experiments performed in duplicate. (B) Supernatants collected from *H. pylori* antigen-stimulated WT, TLR2<sup>-/-</sup> and TLR4<sup>-/-</sup> BMDCs were collected at 4 h, 8 h and 24 h and used to determine (B) IL-10 and (C) MIP-2 levels by ELISA. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ . doi:10.1371/journal.pone.0066914.g004

**A**



**B**





**Figure 5. IRAK-M<sup>-/-</sup> BMDCs do not increase TH<sub>17</sub> induction in vitro.** (A) BMDCs isolated from WT and IRAK-M<sup>-/-</sup> mice were plated and pulsed with OVA for 2 hours before CD4<sup>+</sup> T cells isolated from OT-II Foxp3-GFP animals were added to the wells in the presence of IL-6 and TGFβ for 72 hours. Cells were restimulated with PMA and ionomycin in the presence of monesin, and production of IL-17A in CD4<sup>+</sup> T cells was measured by flow cytometry. (B) Data are representative of three independent experiments. Bar graph represents mean ± SD from data collected from three individual experiments performed in duplicate.  
doi:10.1371/journal.pone.0066914.g005

Flt3L or GM-CSF ( $P < 0.01$ ; Figure 1C) and this response was consistent with using lysates from either the Hp SS1 or the common laboratory strain 26695. Live Hp SS1 was also demonstrated to induce significant levels of IRAK-M expression although less effective than lysate antigen ( $P < 0.01$ ).

### Lack of IRAK-M in BMDCs Results in a More Pro-inflammatory Phenotype in HP-BMDCs

IRAK-M has been shown to play a role in DC activation in a tumor vaccine and in a LPS endotoxin tolerance model of *H. pylori* activation. [41,42] Therefore, we wanted to determine if IRAK-M expression affects cytokine production in HP-BMDCs by comparing WT and IRAK-M<sup>-/-</sup> BMDCs. IRAK-M<sup>-/-</sup> cells have previously been shown to have a more proinflammatory phenotype [33,41]. BMDCs deficient in IRAK-M responded to *H. pylori* antigens by producing TNFα and MIP-2 as early as four hours post activation and peaking at eight hours when levels of both cytokines were significantly higher than for WT BMDCs ( $P < 0.05$ ; Figure 2A and 2B; Supplemental Figure 1). TNFα levels remained higher in IRAK-M<sup>-/-</sup> cells at 24 hours post stimulation ( $P < 0.01$ ). IL-12p70 was also measured but were undetectable (data not shown). This is consistent with our previous observations using *H. felis* activation of BMDC [43]. Conversely, HP-BMDCs secreted significantly less IL-10 compared to WT HP-BMDCs at all time points although levels increased steadily over the 24-hour period (Figure 2C).

Cell surface analysis of activated cells showed that IRAK-M<sup>-/-</sup> HP-BMDCs expressed higher levels of MHC II ( $P < 0.01$ ; Figure 3A), suggesting that IRAK-M normally limits DC activation as measured by MHC II expression in response to *H. pylori* stimulation. Conversely, expression of the down regulatory co-receptor PD-L1 was significantly reduced in activated IRAK-M<sup>-/-</sup> BMDC compared to WT cells ( $P < 0.05$ ; Figure 3B), indicating that IRAK-M normally limits the potential of DC to activate Th cells upon activation with *H. pylori*. Co-receptors CD86 and CD40 however remained comparable between activated IRAK-M<sup>-/-</sup> and WT BMDC (Figures 3C and 3D). Together, these data suggest that in response to *H. pylori* stimulation, IRAK-M expression contributes to a lack of DC maturation and promotes a regulatory phenotype exemplified by IL-10 production.

### IRAK-M upregulation in HP-BMDCs is dependent on both TLR2 and TLR4

TLR2 and TLR4 have been shown to play an important role in *H. pylori* sensing by DCs [31]. We therefore sought to determine if either TLR2 or TLR4 might be important in IRAK-M upregulation by comparing HP-BMDCs from WT, TLR2<sup>-/-</sup> and TLR4<sup>-/-</sup> mice. Whereas WT HP-BMDC displayed a 15-fold increase in IRAK-M expression by eight hours that remained high at 24 hours, Figure 4A illustrates that IRAK-M upregulation in HP-BMDCs is dependent on both TLR2 and TLR4 expression, and that abrogation of either TLR results in a reduction in IRAK-M expression ( $P < 0.05$ ). Additional evidence for the importance of both TLR2 and TLR4 in *H. pylori* lysate induced activation of DC is demonstrated in Figure 4B and 4C where expression of IL-10

and MIP-2 respectively are shown to be significantly reduced compared to BMDC from WT mice ( $P < 0.01$ ). Although expression of both cytokines increased by 24 hours for TLR4 KO cells, these cytokines were largely absent in the cells from TLR2 deficient mice.


### IRAK-M expression in DCs does not affect T<sub>H</sub>17 differentiation in T cells

Since T<sub>H</sub>17 cells have been shown to contribute to the gastritis seen in *H. pylori* infection as well as to protection against *H. pylori* in experimental murine vaccine models [21,44–46], we sought to determine whether the proinflammatory phenotype of IRAK-M<sup>-/-</sup> BMDCs might increase T<sub>H</sub>17 activation using a DC-T cell coculture system. Studies using *H. pylori* stimulated BMDC cells to stimulate splenic CD4<sup>+</sup> cells from mice infected with *H. pylori* showed no increase in either IFNγ or IL-17 producing cells from either WT or IRAK-M<sup>-/-</sup> mice (Supplemental Figure 2). This is consistent with the suppression that occurs in the *H. pylori*-specific T cell response in infected hosts. T cells from transgenic mice with a TCR specific for the OVA antigen were used to increase the frequency of responsive cells. IRAK-M<sup>-/-</sup> BMDCs were similar to WT BMDCs in their ability to generate IL-17A<sup>+</sup>CD4<sup>+</sup> T cells (Figure 5A and 5B). There was no difference in the number of IL-17A<sup>+</sup> T cells following OVA exposure when *H. pylori* activated DC from WT and IRAK-M<sup>-/-</sup> were used as APC cells.


### IRAK-M<sup>-/-</sup> BMDCs are Comparable to WT BMDCs in Generating T<sub>regs</sub>

Since the balance of T<sub>H</sub>17/T<sub>regs</sub> cells contributes to the extent of the inflammatory response in *H. pylori* infection [12], we also sought to determine if T<sub>reg</sub> generation is affected by the lack of IRAK-M in BMDCs using the DC-T cell co-culture system described above. The OVA TCR transgenic mice are also transgenic of FoxP3-GFP expression, providing a convenient marker for FoxP3. HP-BMDC were co-cultured with these T cells and stimulated with OVA and the activated T cells were assessed by flow cytometry for GFP (Figure 6A and 6B). WT and IRAK-M<sup>-/-</sup> BMDCs did not differ in their ability to generate T<sub>regs</sub>. To determine whether IRAK-M expression influences T<sub>reg</sub> induction in response to *H. pylori* in vivo, we sorted CD4<sup>+</sup> GFP<sup>-</sup> T cells from Foxp3-GFP C57BL/6 animals to eliminate natural Treg cells and any preexisting iTreg cells. These GFP negative cells were used for adoptive transfer into WT and IRAK-M<sup>-/-</sup> recipients. Recipient mice were subsequently infected with *H. pylori* and the amount of new FoxP3-GFP expression was determined four weeks later by isolating gastric tissue and using qPCR analysis. *H. pylori* infection in WT animals resulted in the induction of Foxp3 expression in the gastric mucosa (Figure 7,  $P < 0.05$ ). Gastric tissue from IRAK-M<sup>-/-</sup> animals also had increased Foxp3 expression after *H. pylori* infection but levels were comparable to those observed in the gastric tissue of WT animals. Together, this data suggests that the proinflammatory phenotype of IRAK-M<sup>-/-</sup> BMDCs does not affect T<sub>reg</sub> generation.

**A**



**B**




**Figure 6. IRAK-M<sup>-/-</sup> BMDCs do not affect T<sub>reg</sub> induction in vitro.** (A) BMDCs isolated from WT and IRAK-M<sup>-/-</sup> mice were plated and pulsed with OVA for 2 hours before CD4<sup>+</sup> T cells isolated from OT-II Foxp3-GFP animals were added to the wells in the presence of IL-2 and TGFβ for 72 hours. Cells were restimulated with PMA and ionomycin in the presence of monesin, and Foxp3-GFP expression in CD4<sup>+</sup> T cells was measured by flow cytometry. Data are representative of three independent experiments. (B) Bar graph represents mean ± SD from data collected from three individual experiments performed in duplicate.  
doi:10.1371/journal.pone.0066914.g006

## Discussion

Recent studies have demonstrated that DCs play an important immunoregulatory role in *H. pylori* infection and may even impact susceptibility or severity of other diseases such as asthma development [11,12,27,32,47]. An understanding of the molecular pathways that are activated in DCs by *H. pylori*, therefore, could provide significant insight into how immunoregulatory and inflammatory pathways are controlled during the course of infection and how these mechanisms may act more broadly. In the present study, we used a microarray approach to identify molecules in DCs whose expression is changed most significantly by *H. pylori*. We identified IRAK-M as a potential important regulatory protein for further characterization.

By comparing HP-BMDCs to EC-BMDCs in our microarray study, *H. pylori* appeared to be weakly immunogenic as only 10 gene expression changes were apparent after 24 hours. Although this contrasted significantly with the 2162 gene expression changes seen in the EC-BMDCs, our data are consistent with previous microarray analyses on *H. pylori*-activated cells. One study conducted a BMDC microarray following *H. pylori* exposure observed 126 gene expression changes after six hours [30]. A more recent study using *H. pylori* LPS stimulation of HEK293 cells reported only three significant gene expression changes after



**Figure 7. IRAK-M deficiency does not affect iT<sub>reg</sub> generation in vivo.** GFP<sup>-</sup> CD4<sup>+</sup> T cells were isolated from Foxp3-GFP mice and sorted for lack of GFP expression. 2 × 10<sup>5</sup> GFP<sup>-</sup> cells were transferred to the indicated recipient mice i.v. Mice were left untreated or infected with *H. pylori* SS1 for 8 weeks. RNA was isolated from gastric tissue to determine relative GFP expression in the stomach. Each group contained 3–6 mice. Bar graph represents mean ± SD. N.D. = not detectable. \*, P < 0.05.  
doi:10.1371/journal.pone.0066914.g007

24 hours [48]. The low number of gene expression changes may be a reflection of *H. pylori* pathogen associated molecular patterns (PAMPs) having reduced TLR stimulating activity and that after 24 hours, the induced expression of early genes may no longer be evident. The LPS is well documented to lack endotoxin activity, and structural studies confirm that the length and number of its lipid chains do not favor binding to TLR4 [49–51]. The flagellin protein has also been shown to lack the consensus sequence typically associated with binding to TLR5 [52].

Among the TLRs, TLR2 has been demonstrated to play a dominant role on the activation of APC by *H. pylori* [31]. We therefore investigated IRAK-M, a negative regulator of TLR signaling, in greater detail [33]. IRAK-M lacks kinase activity and its expression pattern was initially thought to be restricted to the monocyte/macrophage lineage [53]. It is now known that IRAK-M may also be expressed in dendritic cells and epithelial cells and is a key factor in endotoxin tolerance [33,41,54,55]. IRAK-M<sup>-/-</sup> BMDCs secrete increased levels of T<sub>H</sub>1 cytokines such as IFNγ, and skew the T cell response in vivo towards a more pro-inflammatory phenotype to prolong survival in a tumor vaccine model [41]. In a separate study, IRAK-M<sup>-/-</sup> BMDCs that were tolerized to LPS exhibited higher levels of MHCII and lower levels of IL-10 [42].

In our study, IRAK-M<sup>-/-</sup> BMDCs stimulated with *H. pylori* also displayed a more pro-inflammatory phenotype compared to WT BMDCs. IRAK-M<sup>-/-</sup> BMDCs displayed increased MHC II expression and higher MIP-2, TNFα production, and also produced less immunoregulatory IL-10 and PD-L1. IRAK-M expression was shown to be dependent on TLR2 and TLR4 activation. Both TLR2 and TLR4 have been shown to be important in *H. pylori* infection [31]. Despite the impact of the IRAK-M deficiency on MHC II and cytokine balance in HP-BMDCs, IRAK-M<sup>-/-</sup> DCs failed to change the balance of T cell subsets induced in vitro. DCs have been shown to affect the balance of T<sub>H</sub>17 and T<sub>reg</sub> cells and to influence the outcome of *H. pylori* infection [12]. IRAK-M<sup>-/-</sup> DCs however were comparable to WT DCs in generating T<sub>H</sub>17 and T<sub>reg</sub> in vitro. Additionally, the IRAK-M deficiency in mice did not affect iT<sub>reg</sub> generation in vivo.

IRAK-M appears to play different roles in other infections and can be either beneficial or deleterious to the host [35,36,40,54,56]. For example, IRAK-M deficiency led to improved bacterial clearance and host survival in response to both *Streptococcus pneumoniae* and *Klebsiella pneumoniae* infections [35,36]. In contrast, IRAK-M deficiency is deleterious to the host after influenza infection because the pro-inflammatory phenotype leads to more extensive lung injury in the host [40]. These studies all indicate that IRAK-M helps limit inflammation against pathogenic microbes, an event that can be beneficial to the host, as in the case of influenza infection. Interestingly, gut commensals have also been shown to activate IRAK-M expression and in the absence of both IRAK-M and IL-10, mice were more prone to developing colitis [34].

Of possible relation to *H. pylori* infection, in human genetic studies, IRAK-M has also been associated with asthma in an Italian cohort [57]. The association was not observed in either Japanese or German groups [58,59]. Given the link between *H.*

*pylori* infection and the reduced incidence of asthma in a variety of studies [24,27,32], it will be interesting to further dissect how IRAK-M affects the host response in *H. pylori* infection, and whether it has consequences at other mucosal sites such as the lung. We are currently working on further elucidating the role of IRAK-M in *H. pylori* infection and looking at parameters of the immune response outside of DCs activation.

In summary, we present data to demonstrate that *H. pylori* upregulates IRAK-M expression in DCs. We also show that IRAK-M normally functions to downregulate events associated with immune activation such as MHCII expression and MIP-2 production, and promotes regulatory activity such as the production of IL-10 and expression of PD-L1. IRAK-M expression as well as the activities associated with IRAK-M were dependent upon TLR2, and to a lesser extent TLR4 activation. However, we were unable to demonstrate that IRAK-M plays a role in skewing the balance between T<sub>H</sub>17 and T<sub>reg</sub> cells. Thus, the manifestation of IRAK-M expression may be in limitations in acute or innate host responses. It will be noteworthy to explore how IRAK-M may affect the variety of disease outcomes in *H. pylori* infection and whether there may be any therapeutic potential in modulating IRAK-M expression.

## Supporting Information

**Figure S1 GM-CSF BMDCs and Flt3L BMDCs share similar cytokine profiles when IRAK-M is deficient.**

## References

- Marshall BJ (1995) The 1995 Albert Lasker Medical Research Award. *Helicobacter pylori*. The etiologic agent for peptic ulcer. *J Am Med Assoc* 274: 1064–1066.
- Genta RM, Hamner HW, Graham DY (1993) Gastric lymphoid follicles in *Helicobacter pylori* infection: frequency, distribution, and response to triple therapy. *Hum Pathol* 24: 577–583.
- Marshall BJ, Warren JR (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet* 1: 1311–1315.
- NIH Consensus Conference (1994) *Helicobacter pylori* in peptic ulcer disease. *J Am Med Assoc* 272: 65–69.
- Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, et al. (1991) *Helicobacter pylori* infection and the risk of gastric carcinoma. *N Engl J Med* 325: 1127–1131.
- World Health Organization (1994) Infection with *Helicobacter pylori*. Schistosomes, Liver Flukes and *Helicobacter pylori*. Lyon: International Agency for Research on Cancer. 177–241.
- Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG (1991) *Helicobacter pylori*-associated gastritis and primary B-cell gastric lymphoma. *Lancet* 338: 1175–1176.
- Dooley CP, Cohen H, Fitzgibbons PL, Bauer M, Appleman MD, et al. (1989) Prevalence of *Helicobacter pylori* infection and histologic gastritis in asymptomatic persons. *N Engl J Med* 321: 1562–1566.
- Suerbaum S, Michetti P (2002) *Helicobacter pylori* infection. *N Engl J Med* 347: 1175–1186.
- Anderson KM, Czinn SJ, Redline RW, Blanchard TG (2006) Induction of C/TLA-4-mediated anergy contributes to persistent colonization in the murine model of gastric *Helicobacter pylori* infection. *J Immunol* 176: 5306–5313.
- Arnold IC, Lee JY, Amieva MR, Roers A, Flavell RA, et al. (2011) Tolerance rather than immunity protects from *Helicobacter pylori*-induced gastric preneoplasia. *Gastroenterol* 140: 199–209.
- Kao JY, Zhang M, Miller MJ, Mills JC, Wang B, et al. (2010) *Helicobacter pylori* immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. *Gastroenterol* 138: 1046–1054.
- Lundgren A, Stromberg E, Sjoling A, Lindholm C, Enarsson K, et al. (2005) Mucosal FOXP3-expressing CD4<sup>+</sup> CD25<sup>high</sup> regulatory T cells in *Helicobacter pylori*-infected patients. *Infect Immun* 73: 523–531.
- Lundgren A, Suri-Payer E, Enarsson K, Svennerholm AM, Lundin BS (2003) *Helicobacter pylori*-specific CD4<sup>+</sup> CD25<sup>high</sup> regulatory T cells suppress memory T-cell responses to *H. pylori* in infected individuals. *Infect Immun* 71: 1755–1762.
- Rad R, Brenner L, Bauer S, Schwendy S, Layland L, et al. (2006) CD25<sup>+</sup>/Foxp3<sup>+</sup> T cells regulate gastric inflammation and *Helicobacter pylori* colonization in vivo. *Gastroenterol* 131: 525–537.
- Raghavan S, Fredriksson M, Svennerholm AM, Holmgren J, Suri-Payer E (2003) Absence of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells is associated with a loss of regulation leading to increased pathology in *Helicobacter pylori*-infected mice. *Clin Exp Immunol* 132: 393–400.
- Raghavan S, Suri-Payer E, Holmgren J (2004) Antigen-specific in vitro suppression of murine *Helicobacter pylori*-reactive immunopathological T cells by CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells. *Scand J Immunol* 60: 82–88.
- Bamford KB, Fan X, Crowe SE, Leary JF, Gourley WK, et al. (1998) Lymphocytes in the human gastric mucosa during *Helicobacter pylori* have a T helper cell 1 phenotype. *Gastroenterol* 114: 482–492.
- Eaton KA, Mefford M, Thevenot T (2001) The role of T cell subsets and cytokines in the pathogenesis of *Helicobacter pylori* gastritis in mice. *J Immunol* 166: 7456–7461.
- Fan XJ, Chua A, Shahi CN, McDevitt J, Keeling PWN, et al. (1994) Gastric T lymphocyte responses to *Helicobacter pylori* colonisation. *Gut* 35: 1379–1384.
- Horvath DJ, Jr., Washington MK, Cope VA, Algood HM (2012) IL-23 contributes to control of chronic *Helicobacter pylori* infection and the development of T helper responses in a mouse model. *Front Immunol* 3: 56.
- Karttunen RA, Karttunen TJ, Yousfi MM, El-Zimaity H, Graham DY, et al. (1997) Expression of mRNA for interferon-gamma, interleukin-10, and interleukin-12 (p40) in normal gastric mucosa and in mucosa infected with *Helicobacter pylori*. *Scand J Gastroenterol* 32: 22–27.
- Roth KA, Kapadia SB, Martin SM, Lorenz RG (1999) Cellular immune responses are essential for the development of *Helicobacter felis*-associated gastric pathology. *J Immunol* 163: 1490–1497.
- Holster IL, Vila AM, Caudri D, den Hoed CM, Perez-Perez GI, et al. (2012) The impact of *Helicobacter pylori* on atopic disorders in childhood. *Helicobacter* 17: 232–237.
- Blaser MJ (2010) *Helicobacter pylori* and esophageal disease: wake-up call? *Gastroenterol* 139: 1819–1822.
- Sonnenberg A, Lash RH, Genta RM (2010) A national study of *Helicobacter pylori* infection in gastric biopsy specimens. *Gastroenterol* 139: 1901–1894 e1892; quiz e1812.
- Oerli M, Sundquist M, Hitzler I, Engler DB, Arnold IC, et al. (2012) DC-derived IL-18 drives Treg differentiation, murine *Helicobacter pylori*-specific immune tolerance, and asthma protection. *J Clin Invest* 122: 1082–1096.
- Steinman RM (2012) Decisions about dendritic cells: past, present, and future. *Annu Rev Immunol* 30: 1–22.
- Steinman RM, Cohn ZA (1973) Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. *J Exp Med* 137: 1142–1162.
- Rad R, Brenner L, Krug A, Volland P, Mages J, et al. (2007) Toll-like receptor-dependent activation of antigen-presenting cells affects adaptive immunity to *Helicobacter pylori*. *Gastroenterol* 133: 150–163 e153.
- Rad R, Ballhorn W, Volland P, Eisenacher K, Mages J, et al. (2009) Extracellular and intracellular pattern recognition receptors cooperate in the recognition of *Helicobacter pylori*. *Gastroenterol* 136: 2247–2257.

32. Arnold IC, Dehzad N, Reuter S, Martin H, Becher B, et al. (2011) *Helicobacter pylori* infection prevents allergic asthma in mouse models through the induction of regulatory T cells. *J Clin Invest* 121: 3088–3093.
33. Kobayashi K, Hernandez LD, Galan JE, Janeway CA, Jr., Medzhitov R, et al. (2002) IRAK-M is a negative regulator of Toll-like receptor signaling. *Cell* 110: 191–202.
34. Biswas A, Wilmanski J, Forsman H, Hrnčir T, Hao L, et al. (2011) Negative regulation of Toll-like receptor signaling plays an essential role in homeostasis of the intestine. *Eur J Immunol* 41: 182–194.
35. Hoogerwerf JJ, van der Windt GJ, Blok DC, Hoogendijk AJ, De Vos AF, et al. (2012) Interleukin-1 receptor-associated kinase M-deficient mice demonstrate an improved host defense during Gram-negative pneumonia. *Mol Med* 18: 1067–1075.
36. van der Windt GJ, Blok DC, Hoogerwerf JJ, Lammers AJ, de Vos AF, et al. (2012) Interleukin 1 receptor-associated kinase m impairs host defense during pneumococcal pneumonia. *J Infect Dis* 205: 1849–1857.
37. Skupsky J, Zhang AH, Su Y, Scott DW (2010) B-cell-delivered gene therapy induces functional T regulatory cells and leads to a loss of antigen-specific effector cells. *Mol Ther* 18: 1527–1535.
38. Lee A, O'Rourke J, De Ungria MC, Robertson B, Daskalopoulos G, et al. (1997) A standardized mouse model of *Helicobacter pylori* infection: introducing the Sydney strain. *Gastroenterol* 112: 1386–1397.
39. Rahn W, Redline RW, Blanchard TG (2004) Molecular analysis of *Helicobacter pylori*-associated gastric inflammation in naive versus previously immunized mice. *Vaccine* 23: 807–818.
40. Seki M, Kohno S, Newstead MW, Zeng X, Bhan U, et al. (2010) Critical role of IL-1 receptor-associated kinase-M in regulating chemokine-dependent deleterious inflammation in murine influenza pneumonia. *J Immunol* 184: 1410–1418.
41. Turnis ME, Song XT, Bear A, Foster AE, Gottschalk S, et al. (2010) IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity. *J Immunol* 185: 4223–4232.
42. Cole TS, Zhang M, Standiford TJ, Newstead M, Luther J, et al. (2012) IRAK-M modulates expression of IL-10 and cell surface markers CD80 and MHC II after bacterial re-stimulation of tolerized dendritic cells. *Immunol Lett* 144: 49–59.
43. Drakes ML, Czinn SJ, Blanchard TG (2006) Regulation of murine dendritic cell immune responses by *Helicobacter felis* antigen. *Infect Immun* 74: 4624–4633.
44. DeLyria ES, Redline RW, Blanchard TG (2009) Vaccination of mice against *H. pylori* induces a strong Th-17 response and immunity that is neutrophil dependent. *Gastroenterol* 136: 247–256.
45. Shiomi S, Toriie A, Imamura S, Konishi H, Mitsufuji S, et al. (2008) IL-17 is involved in *Helicobacter pylori*-induced gastric inflammatory responses in a mouse model. *Helicobacter* 13: 518–524.
46. Velin D, Favre L, Bernasconi E, Bachmann D, Pythoud C, et al. (2009) Interleukin-17 is a critical mediator of vaccine-induced reduction of *Helicobacter* infection in the mouse model. *Gastroenterol* 136: 2237–2246 e2231.
47. Hitzler I, Oertli M, Becher B, Agger EM, Muller A (2011) Dendritic cells prevent rather than promote immunity conferred by a *Helicobacter* vaccine using a mycobacterial adjuvant. *Gastroenterol* 141: 186–196, 196 e181.
48. Smith SM, Moran AP, Duggan SP, Ahmed SE, Mohamed AS, et al. (2011) Tribbles 3: a novel regulator of TLR2-mediated signaling in response to *Helicobacter pylori* lipopolysaccharide. *J Immunol* 186: 2462–2471.
49. Mandell L, Moran AP, Cocchiarella A, Houghton J, Taylor N, et al. (2004) Intact gram-negative *Helicobacter pylori*, *Helicobacter felis*, and *Helicobacter hepaticus* bacteria activate innate immunity via toll-like receptor 2 but not toll-like receptor 4. *Infect Immun* 72: 6446–6454.
50. Suda Y, Ogawa T, Kashihara W, Oikawa M, Shimoyama T, et al. (1997) Chemical structure of lipid A from *Helicobacter pylori* strain 206-1 lipopolysaccharide. *J Biochem* 121: 1129–1133.
51. Tran AX, Stead CM, Trent MS (2005) Remodeling of *Helicobacter pylori* lipopolysaccharide. *J Endotoxin Res* 11: 161–166.
52. Andersen-Nissen E, Smith KD, Strobe KL, Barrett SL, Cookson BT, et al. (2005) Evasion of Toll-like receptor 5 by flagellated bacteria. *Proc Natl Acad Sci U S A* 102: 9247–9252.
53. Wesche H, Gao X, Li X, Kirschning CJ, Stark GR, et al. (1999) IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. *J Biol Chem* 274: 19403–19410.
54. Takahashi N, Honda T, Domon H, Nakajima T, Tabeta K, et al. (2010) Interleukin-1 receptor-associated kinase-M in gingival epithelial cells attenuates the inflammatory response elicited by *Porphyromonas gingivalis*. *J Periodontol Res* 45: 512–519.
55. van 't Veer C, van den Pangaart PS, van Zoelen MA, de Kruif M, Birjmohun RS, et al. (2007) Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. *J Immunol* 179: 7110–7120.
56. Deng JC, Cheng G, Newstead MW, Zeng X, Kobayashi K, et al. (2006) Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M. *J Clin Invest* 116: 2532–2542.
57. Balaci L, Spada MC, Olla N, Sole G, Loddo L, et al. (2007) IRAK-M is involved in the pathogenesis of early-onset persistent asthma. *Am J Hum Genet* 80: 1103–1114.
58. Beygo J, Parwez Q, Petrasch-Parwez E, Epplen JT, Hoffjan S (2009) No evidence of an association between polymorphisms in the IRAK-M gene and atopic dermatitis in a German cohort. *Mol Cell Probes* 23: 16–19.
59. Nakashima K, Hirota T, Obara K, Shimizu M, Jodo A, et al. (2006) An association study of asthma and related phenotypes with polymorphisms in negative regulator molecules of the TLR signaling pathway. *J Hum Genet* 51: 284–291.